A Detailed Physiologically Based Model to Simulate the Pharmacokinetics and Hormonal Pharmacodynamics of Enalapril on the Circulating Endocrine Renin-Angiotensin-Aldosterone System
Open Access
- 1 January 2013
- journal article
- Published by Frontiers Media SA in Frontiers in Physiology
Abstract
The renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathogenesis of cardiovascular disorders including hypertension and is one of the most important targets for drugs. A whole body physiologically based pharmacokinetic (wb PBPK) model integrating this hormone circulation system and its inhibition can be used to explore the influence of drugs that interfere with this system, and thus to improve the understanding of interactions between drugs and the target system. In this study, we describe the development of a mechanistic RAAS model and exemplify drug action by a simulation of enalapril administration. Enalapril and its metabolite enalaprilat are potent inhibitors of the angiotensin-converting-enzyme (ACE). To this end, a coupled dynamic parent-metabolite PBPK model was developed and linked with the RAAS model that consists of seven coupled PBPK models for aldosterone, ACE, angiotensin 1, angiotensin 2, angiotensin 2 receptor type 1, renin, and prorenin. The results indicate that the model represents the interactions in the RAAS in response to the pharmacokinetics (PK) and pharmacodynamics (PD) of enalapril and enalaprilat in an accurate manner. The full set of RAAS-hormone profiles and interactions are consistently described at pre- and post-administration steady state as well as during their dynamic transition and show a good agreement with literature data. The model allows a simultaneous representation of the parent-metabolite conversion to the active form as well as the effect of the drug on the hormone levels, offering a detailed mechanistic insight into the hormone cascade and its inhibition. This model constitutes a first major step to establish a PBPK-PD-model including the PK and the mode of action (MoA) of a drug acting on a dynamic RAAS that can be further used to link to clinical endpoints such as blood pressure.Keywords
This publication has 62 references indexed in Scilit:
- Heart Disease and Stroke Statistics—2012 UpdateCirculation, 2012
- Reorganizing the protein space at the Universal Protein Resource (UniProt)Nucleic Acids Research, 2011
- PubChem's BioAssay DatabaseNucleic Acids Research, 2011
- DrugBank 3.0: a comprehensive resource for 'Omics' research on drugsNucleic Acids Research, 2010
- Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combinationVascular Health and Risk Management, 2010
- Current computational models do not reveal the importance of the nervous system in long‐term control of arterial pressureExperimental Physiology, 2009
- Urinary Angiotensinogen as a Novel Biomarker of the Intrarenal Renin-Angiotensin System Status in Hypertensive PatientsHypertension, 2009
- Motivations and Methods for Analyzing Pulsatile Hormone SecretionEndocrine Reviews, 2008
- HMDB: a knowledgebase for the human metabolomeNucleic Acids Research, 2008
- Novel sandwich ELISA for human angiotensinogenAmerican Journal of Physiology-Renal Physiology, 2007